Is tirzepatide approved?

Yes, as a prescription medicine: Mounjaro for type-2 diabetes and Zepbound for weight management, among other markets. The research material we supply is not those products and is for laboratory use only.

What has tirzepatide research looked at?

The SURPASS trials in type-2 diabetes and the SURMOUNT trials in obesity, which measured HbA1c and body-weight change against placebo and comparators. The cited studies are listed above.

A single peptide that activates both the GIP and GLP-1 receptors, described as a dual incretin agonist.

Tirzepatide research: what the studies have looked at

This page summarises the published clinical research on tirzepatide, for reference. It sets out what each trial tested and in whom, not an outcome for any individual, and it is not medical advice. Tirzepatide is the active ingredient in approved medicines, but the material we supply under this name is a research chemical for laboratory use only and is not those products.

What tirzepatide is

Tirzepatide is a dual agonist: one peptide that activates both the GIP and the GLP-1 receptor. It is approved by the US FDA and other regulators and sold as Mounjaro for type-2 diabetes and as Zepbound for weight management. Those are finished, quality-controlled medicines dispensed by prescription. The powder we supply has the same chemical identity but is unapproved research material, not the licensed product, and it is not for human use.

What the studies investigated

Rosenstock et al. (2021), The Lancet 398(10295):143-155 (SURPASS-1). Human, phase-3, type-2 diabetes. Investigated glycaemic control and body weight as monotherapy against placebo Source.

Frías et al. (2021), New England Journal of Medicine 385(6):503-515 (SURPASS-2). Human, phase-3, type-2 diabetes. Investigated HbA1c change over 40 weeks against a GLP-1 agonist comparator Source.

Jastreboff et al. (2022), New England Journal of Medicine 387(3):205-216 (SURMOUNT-1). Human, phase-3, obesity. Investigated body-weight change over 72 weeks against placebo Source.

Garvey et al. (2023), The Lancet 402(10402):613-626 (SURMOUNT-2). Human, phase-3, obesity with type-2 diabetes. Investigated body-weight change over 72 weeks against placebo Source.

Mechanism, as described in the literature

By engaging the GIP and GLP-1 receptors together, the drug is described as amplifying the incretin response, the body’s own post-meal insulin and satiety signalling. The trials above reported change in HbA1c and body weight against placebo and against a single GLP-1 agonist over set periods. They are efficacy and safety trials in defined patient groups, run under medical supervision, and they do not describe what a research powder does outside that setting.

The material we supply

We supply tirzepatide as a research chemical, released against a written specification with a batch certificate of analysis. It is not Mounjaro, Zepbound or any other medicine, and it is not for human or animal use. For the vial sizes, the price per mg and how to order, see where to buy tirzepatide wholesale; the COA lookup pulls the certificate for any batch. The references above link to each trial’s record; this summary is for research and educational reference only.